Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients

被引:9
|
作者
Mondelo-Macia, Patricia [1 ,2 ]
Garcia-Gonzalez, Jorge [3 ,4 ,5 ]
Abalo, Alicia [1 ]
Mosquera-Presedo, Manuel [2 ]
Aguin, Santiago [3 ,4 ]
Mateos, Maria [3 ,4 ]
Lopez-Lopez, Rafael [3 ,4 ,5 ]
Leon-Mateos, Luis [2 ,3 ,4 ,5 ]
Muinelo-Romay, Laura [1 ,5 ]
Diaz-Pena, Roberto [1 ,6 ]
机构
[1] Hlth Res Inst Santiago IDIS, Liquid Biopsy Anal Unit, Translat Med Oncol Oncomet, Santiago De Compostela, Spain
[2] Univ Santiago de Compostela USC, Santiago De Compostela, Spain
[3] Complexo Hosp Univ Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
[4] Hlth Res Inst Santiago IDIS, Translat Med Oncol Oncomet, Santiago De Compostela, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Univ Autonoma Chile, Fac Hlth Sci, Inst Biomed Sci, Lab Cellular & Mol Pathol, Talca, Chile
关键词
Small cell lung cancer; liquid biopsy; cell free DNA; circulating tumor cells (CTCs); prognostic biomarkers; SURVIVAL; IMMUNOTHERAPY; PROGRESSION; PREDICTION; PROFILES; INSIGHTS; BENEFIT; CTDNA;
D O I
10.21037/tlcr-22-273
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lack of biomarkers for treatment selection and monitoring in small cell lung cancer (SCLC) patients with the limited therapeutic options, result in poor outcomes. Therefore, new prognostic biomarkers are needed to improve their management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor cells (CTCs) have been less explored in SCLC. Methods: We quantified cfDNA in 46 SCLC patients at different times during first-line of chemotherapy or chemo-immunotherapy. Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch (R) system. The possible association between both biomarkers and patients' outcomes was investigated in order to develop a prognostic model. Results: High cfDNA levels before therapy were associated with shorter progression-free survival (PFS) and overall survival (OS). Furthermore, cfDNA levels at 3 weeks and at progression disease were also associated with patients' outcomes. Multivariate analyses confirmed the independence of cfDNA levels as a prognostic biomarker. Finally, the three-risk category prognostic model developed included Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender and baseline cfDNA levels was associated with a higher risk of progression and death. Conclusions: We confirmed the prognostic utility of cfDNA quantitative analysis in SCLC patients before and during therapy. Our novel risk prognostic model in clinical practice will allow to identify patients who could benefit with actual therapies.
引用
收藏
页码:1995 / +
页数:19
相关论文
共 50 条
  • [1] Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
    Nie, Kun
    Jia, Yujie
    Zhang, Xuezhu
    [J]. TUMOR BIOLOGY, 2015, 36 (01) : 7 - 19
  • [2] Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
    Coco, Simona
    Alama, Angela
    Vanni, Irene
    Fontana, Vincenzo
    Genova, Carlo
    Dal Bello, Maria Giovanna
    Truini, Anna
    Rijavec, Erika
    Biello, Federica
    Sini, Claudio
    Burrafato, Giovanni
    Maggioni, Claudia
    Barletta, Giulia
    Grossi, Francesco
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [3] Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer
    Morgensztern, Daniel
    Devarakonda, Siddhartha
    Masood, Ashiq
    Waqar, Saiama
    Carmack, Alicia
    Banks, Kimberly
    Lanman, Richard
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S717 - S718
  • [4] Detection of circulating cell-free tumor DNA (ctDNA) in patients with small cell lung cancer (SCLC)
    Mohan, Sumitra
    Foy, Victoria
    Leong, Hui Sun
    Schofield, Pieta G.
    Ayub, Mahmood
    Smith, Nigel K.
    Sahoo, Sudhakar
    Sik-Kim, Chang
    Priest, Lynsey
    Carter, Mathew
    Carr, Hedley T.
    Miller, Crispin
    Finn-Faivre, Corinne
    Blackhall, Fiona
    Rothwell, Dominic G.
    Dive, Caroline
    Brady, Gerard
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer
    Jin, Nana
    Kan, Chau-Ming
    Pei, Xiao Meng
    Cheung, Wing Lam
    Ng, Simon Siu Man
    Wong, Heong Ting
    Cheng, Hennie Yuk-Lin
    Leung, Wing Wa
    Wong, Yee Ni
    Tsang, Hin Fung
    Chan, Amanda Kit Ching
    Wong, Yin Kwan Evelyn
    Cho, William Chi Shing
    Chan, John Kwok Cheung
    Tai, William Chi Shing
    Chan, Ting-Fung
    Wong, Sze Chuen Cesar
    Yim, Aldrin Kay-Yuen
    Yu, Allen Chi-Shing
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] A Pilot Study to Assess Circulating Tumor Cells, Circulating Tumor Cell DNA and Cell Free DNA in Patients with Small Cell Lung Cancer
    Aggarwal, Charu
    Badola, Sunita
    Shin, Hyunjin
    Bedford, Lisa
    Collins, Sabrina
    Derk, Blair
    Fostel, Jen
    Ecsedy, Jeffrey
    Evans, Tracey
    Bauml, Joshua
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    Niu, Huifeng
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1527 - S1527
  • [7] Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
    Alama, Angela
    Coco, Simona
    Genova, Carlo
    Rossi, Giovanni
    Fontana, Vincenzo
    Tagliamento, Marco
    Dal Bello, Maria Giovanna
    Rosa, Alessandra
    Boccardo, Simona
    Rijavec, Erika
    Biello, Federica
    Longo, Luca
    Cavalieri, Zita
    Bruzzo, Cristina
    Grossi, Francesco
    [J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07):
  • [8] New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA
    Durendez-Saez, Elena
    Azkarate, Aitor
    Meri, Marina
    Calabuig-Farinas, Silvia
    Aguilar-Gallardo, Cristobal
    Blasco, Ana
    Jantus-Lewintre, Eloisa
    Camps, Carlos
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 : S1332 - S1345
  • [9] Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.
    Morgensztern, Daniel
    Devarakonda, Siddhartha H. K.
    Masood, Ashiq
    Waqar, Saiama Naheed
    Carmack, Alicia C.
    Banks, Kimberly C.
    Lanman, Richard Burnham
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy"
    Nicolazzo, Chiara
    Raimondi, Cristina
    Loreni, Flavia
    Gazzaniga, Paola
    Gradilone, Angela
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (06)